Lebwohl, M., Strober, B., Linaberry, M., Hoyt, K., Banerjee, S., Kisa, R.M. and Mehta, N.N. 2023. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: evaluation of lipid parameters in the phase 3 POETYK PSO-1 and PSO-2 trials. SKIN The Journal of Cutaneous Medicine. 7, 2 (Mar. 2023), s115. DOI:https://doi.org/10.25251/skin.7.supp.115.